8879565333
Category: Equity: Sectoral-Pharma and Healthcare |
Launch Date: 01-06-2004 |
Asset Class: Equity |
Benchmark: BSE Healthcare TRI |
Expense Ratio: 1.8% As on (31-08-2025) |
Status: Open Ended Schemes |
Minimum Investment: 5000.0 |
Minimum Topup: 1000.0 |
Total Assets: 8,357.8 Cr As on (29-08-2025) |
Turn over: 12% |
Sailesh Raj Bhan
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.
Rolling returns are the annualized returns of the scheme taken for a specified period (rolling returns period) on every day/week/month and taken till the last day of the duration. In this chart we are showing the annualized returns over the rolling returns period on every day from the start date and comparing it with the benchmark. Rolling returns is the best measure of a fund's performance. Trailing returns have a recency bias and point to point returns are specific to the period in consideration. Rolling returns, on the other hand, measures the fund's absolute and relative performance across all timescales, without bias.
Key Statistics | Volatility | Sharpe Ratio | Alpha | Beta | Yield to Maturity | Average Maturity |
---|---|---|---|---|---|---|
Nippon India Pharma Fund-Growth Plan-Growth Option | 14.36 | 1.06 | 2.8 | 0.86 | - | - |
Equity: Sectoral-Pharma and Healthcare | - | - | - | - | - | - |
Portfolio as on
Sector | Allocation (%) |
---|
Sector | Allocation (%) |
---|